Complications of Tumor Necrosis Factor–α Blockade in Chronic Granulomatous Disease–Related Colitis

Abstract

Infliximab use in the treatment of CGD inflammatory bowel disease requires aggressive antimicrobial prophylaxis, assiduous surveillance for infection, and vigilance for untoward gastrointestinal complications. This experience suggests that infliximab therapy is effective but has untoward consequences in patients with CGD.